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Abstract
Introduction: Activation of the phosphatidylinositol 3-kinase (PI3K) pathway in estrogen receptor α (ER)-positive
breast cancer is associated with reduced ER expression and activity, luminal B subtype, and poor outcome. Phosphatase
and tensin homolog (PTEN), a negative regulator of this pathway, is typically lost in ER-negative breast cancer. We set
out to clarify the role of reduced PTEN levels in endocrine resistance, and to explore the combination of newly
developed PI3K downstream kinase inhibitors to overcome this resistance.
Methods: Altered cellular signaling, gene expression, and endocrine sensitivity were determined in inducible
PTEN-knockdown ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer cell
and/or xenograft models. Single or two-agent combinations of kinase inhibitors were examined to improve
endocrine therapy.
Results: Moderate PTEN reduction was sufficient to enhance PI3K signaling, generate a gene signature
associated with the luminal B subtype of breast cancer, and cause endocrine resistance in vitro and in vivo.
The mammalian target of rapamycin (mTOR), protein kinase B (AKT), or mitogen-activated protein kinase kinase (MEK)
inhibitors, alone or in combination, improved endocrine therapy, but the efficacy varied by PTEN levels, type of
endocrine therapy, and the specific inhibitor(s). A single-agent AKT inhibitor combined with fulvestrant conferred
superior efficacy in overcoming resistance, inducing apoptosis and tumor regression.
Conclusions: Moderate reduction in PTEN, without complete loss, can activate the PI3K pathway to cause endocrine
resistance in ER-positive breast cancer, which can be overcome by combining endocrine therapy with inhibitors of the
PI3K pathway. Our data suggests that the ER degrader fulvestrant, to block both ligand-dependent and -independent
ER signaling, combined with an AKT inhibitor is an effective strategy to test in patients.
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Introduction
The phosphatidylinositol 3-kinase (PI3K) pathway is
frequently altered in breast cancer, with more than
70% of tumors displaying genetic aberrations in at least
one component of this pathway [1]. Molecular profil-
ing stratifies estrogen receptor (ER)-positive (+) breast
cancer into luminal A and luminal B subtypes. The lu-
minal B subtype is more aggressive and more resistant
to endocrine therapy [2]. We have previously shown
that PI3K pathway activation signatures in ER+ breast
cancer are associated with reduced ER and classical ER
activity, luminal B subtype, and worse outcome [3].
Furthermore, PI3K downstream signaling phosphory-
lates and activates ER and co-activators such as steroid
receptor coactivator-3 (SRC3) in a ligand-independent
manner, rendering this receptor unresponsive to tam-
oxifen or aromatase inhibitors [4]. Surprisingly, onco-
genic mutations in PIK3CA, the gene encoding the
catalytic subunit of PI3K, are associated with the lu-
minal A subtype, high ER, and better clinical outcome
in ER+ breast cancer patients receiving endocrine
therapy [5,6]. These mutations are associated with only
weak activation of the PI3K pathway, probably due to
subsequent negative-feedback regulation. On the other
hand, loss of phosphatase and tensin homolog (PTEN),
a negative regulator of the PI3K pathway, activates
downstream protein kinase B (AKT)/mammalian tar-
get of rapamycin (mTOR) signaling and may contrib-
ute to endocrine therapy resistance [7-9]. Interestingly,
we and others have reported that even moderate re-
duction in PTEN determined by reverse-phase protein
array (RPPA) is associated with PI3K downstream
pathway activation [3,6]. Furthermore, PTEN dose-
dependency was highlighted in a PTEN hypomorphic
mouse model showing that subtle downregulation of
PTEN by only 20% can lead to breast tumors with high
penetrance [10]. Typically lost in ER-negative breast
cancer, PTEN protein is decreased in more than 50% of
ER+ breast cancer [6]. A recent TCGA (The Cancer
Genome Atlas) study showed that PTEN gene aberra-
tions (mutations or loss) are twice as frequent in lu-
minal B as in luminal A breast cancer (24% vs. 13%). In
contrast, as found in the previous studies mentioned
above [5,6], frequency of PIK3CA mutations was
shown to be higher in luminal A than in luminal B
breast cancer [11].
Therefore, we hypothesized that a moderate reduction
in PTEN contributes to the endocrine resistance seen in
the luminal B subtype via activation of the PI3K path-
way. We further hypothesized that using the ER de-
grader fulvestrant to inhibit both ligand-dependent
and -independent receptor activation combined with in-
hibitors of PI3K downstream signaling would be most
effective in overcoming this type of resistance.
In order to fully address the impact of reduced PTEN
levels on PI3K activation and endocrine response, we
created models of ER+/human epidermal growth factor
receptor 2 (HER2)-negative (−) breast cancer with re-
duced PTEN by inducible knockdown (KD). We found
that moderate reductions in PTEN, commonly seen in
ER+ breast cancer, activate the PI3K pathway, and re-
duce ER level and classical transcriptional activity.
PTEN-KD generates a gene expression signature similar
to luminal B breast cancer, leading to resistance to endo-
crine therapy in vitro and in vivo. Fulvestrant combined
with an AKT inhibitor alone or combined with a
mitogen-activated protein kinase kinase (MEK) inhibitor
is the optimal approach to overcome the resistance.
Methods
Cell culture and reagents
Human breast cancer cell lines MCF7L (from Dr. Marc
Lippman) and BT483 and T47D (both from the American
Type Culture Collection) were all authenticated and
maintained in RPMI/1640 medium supplemented with
10% heat-inactivated fetal bovine serum (FBS) and 1%
penicillin/streptomycin/glutamine, and incubated at
37°C in 5% CO2. The mTOR inhibitor (AZD2014),
AKT inhibitor (AZD5363), MEK inhibitor (selumetinib
(AZD6244, ARRY-142886)), and fulvestrant were pro-
vided by AstraZeneca. β-estradiol (E2) and 4-OH-
tamoxifen for in vitro, and tamoxifen citrate for in vivo
experiments were purchased from Sigma-Aldrich (St
Louis, MO, USA).
pINDUCER lentiviral system
All procedures were done as described [12]. Live animal
imaging was performed as previously described [13].
Cell growth assay
Cells were pre-treated in phenol-red free (PRF) medium
with 5% charcoal stripped-FBS (CS-FBS) and −/+doxy-
cycline (Dox) three days before treatment for an additional
five to ten days, as indicated. The starting number of cells
in each experiment was identical across all treatment
groups. Culture medium with drugs was replaced every
three days. Cell growth was measured either by colori-
metric methylene blue staining [14] every two days or
daily real-time in situ cell cytometry (Celigo, Nexcelom
Bioscience, Lawrence, MA, USA). Cell growth under
estrogen (E2) was set as the normalization control. All
the anti-estrogen treatments of estrogen deprivation
(ED), tamoxifen (Tam), and fulvestrant (Ful) were in
the absence of E2. The relative cell growth was deter-
mined by (cell number or OD at dayn - cell number or
OD at day0) Treatment/(cell number or OD at dayn - cell
number or OD at day0) E2 × 100%.
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Immunoblotting assay
This assay was performed as described previously [14].
Primary antibodies used in this study are: ER (6F11) from
Abcam, Cambridge, MA, USA; PR (sc-7208) and BCL2
(sc-509) from Santa Cruz Biotechnology, Santa Cruz, CA,
USA; P-AKT-Thr308 (#2214) and P-AKT-Ser473 (#2118)
from Epitomics, Burlingame, CA, USA; P-PRAS40-Thr246
(#2997), P-GSK3-Ser9 (#9323), P-ERK1/2-Thr202/Tyr204
(#9101), P-S6-Ser240/244 (#2211), P-4EBP1-Thr37/46
(#9459), P-mTOR-Ser2448 (#2971), AKT (#9272), ERK1/2
(#9102), GSK-3β (#9832), PTEN (#9559), β-actin (#4970),
and c-PARP (#9541) from Cell Signaling Technology,
Danvers, MA, USA. All our shown Western blotting im-
ages are from the same gel with the same exposure to allow
for a complete comparison between lines and across
treatments.
Quantitative reverse transcription-polymerase chain
reaction (qRT-PCR)
The assay procedure was described previously [3]. Target
primer sequences are as follows: PTEN forward GTAAC
GACTTCTCCATCTC, reverse ATCCACAGCAGGTAT
TATG; GREB1 forward TCATCTTGTTCATCTTGTT
CAGT, reverse GCATCTCAACCTTCTCATCTT; BCL2
forward GGGGAGGATTGTGGCCTTC, reverse CAGG
GCGATGTTGTCCACC; ER-α forward AACCGAGAT
GATGTAGCCAGC, reverse CAGGAACCAGGGAAAA
TGTG; PR forward GATGCTGTATTTTGCACCTGA
TCTA, reverse GAACTCTTCTTGGCTAACTTGAAG
CT; CAV1 forward GGTCAACCGCGACCCTAAA, re-
verse CCTTCCAAATGCCGTCAAA; GAPDH forward
AAGGTGAAGGTCGGAGTC, reverse GGGGTCATT-
GATGGCAAC.
Cell cycle and apoptosis flow cytometry
Cells were trypsinized and stained with SytoxBlue (Invitro-
gen, Carlsbad, CA, USA) to distinguish the dead cells.
Vybrant DyeCycle Ruby stain (Invitrogen) was applied to
quantify DNA in living cells for 30 minutes in 37°C. Stained
cells were analyzed by flow cytometry (LSRFortessa, BD
Biosciences, Franklin Lakes, NJ, USA) using filter1 (Em:
680 nm) for signal acquisition, and analysis was done by
using Flowjo (v9) software (Tree Star Inc, Ashland, OR,
USA). After 48 hours of treatment, cells were trypsinized
and stained with Annexin V-APC (Invitrogen) and Sytox-
Blue (Invitrogen) for 15 minutes before being analyzed by
flow cytometry (LSRFortessa, BD Biosciences) using filter1
(Em: 680 nm) and filter2 (Em: 480 nm) for Annexin V and
SytoxBlue staining, respectively. Data analysis was done by
using Flowjo (v9) software (Tree Star).
Colony and tumorsphere formation assay
MCF7L-shPTEN cells were seeded at 6,000 per 6-cm dish
and treated as before. After three weeks of endocrine
treatment, colonies were stained by crystal violet and
counted by ImageJ software [15]. BT483-shPTEN cells
were seeded at 3,000 per well in a low-adhesive 96-well
plate and prepared as before. The tumorspheres were
scanned and counted by in situ cell cytometry two weeks
after endocrine treatment (diameter >50 μm as threshold),
according to the manufacturer’s instruction.
Immunohistochemical (IHC) staining
This assay was performed as described previously [14].
Briefly, paraffin-embedded blocks of xenograft tumor tis-
sues were organized into a 3-mm core tissue array and
IHC staining was performed on 3-micron sections from
these arrays. By using a PTEN index array as an internal
validation control, an optimized protocol for PTEN IHC
staining was developed and followed. Briefly, freshly cut
slides were deparaffinized and subjected to epitope retrieval
in 0.1 M Tris-HCl buffer (pH 9.0). After blocking in 3%
hydrogen peroxide for 5 minutes, slides were incubated
with PTEN antibody (#9188, Cell Signaling Technology) at
a dilution of 1:100 for one hour. Immunodetection was per-
formed with the EnVision + System (Dako Cytomation,
Carpinteria, CA, USA). The cytoplasmic staining of PTEN
or pAKT in tumors was scored by Allred score [16]. Ki67
was scored by percentage of positive cells.
Gene expression analysis
The original RNA-seq data of MCF7L-shPTEN cells were
deposited into the GEO database (GSE53300). TCGA data
were accessed from the TCGA data portal [11,17]. The
mega-set Compendium of breast cancer gene expression
profiles was previously reported [18]. RNA samples were
extracted by using Qiagen (Germantown, MD, USA)
RNeasy Mini kit and labeled with Illumina (San Diego,
CA, USA) TruSeq RNA kit. Next-generation RNA-seq
was performed in Illumina RNA-seq platform and
scanned by HiSeq 2000. We used the freely available
Cufflinks/Cuffdiff software package (v1.3.0) to identify
differences in expression of genes/isoforms between
the two samples [19]. In brief, this approach employs a
statistical approach based on Jensen-Shannon diver-
gence, looking for differences in the distribution of
expression of isoforms between the sample sets. Differ-
entially expressed genes between PTEN-wild-type
(WT) and -KD cells were chosen by FDR <0.05 and
their values were represented by Java TreeView [20].
Pearson’s correlation (represented as a t statistic or ‘t
score’) was used as previously described [21,22], in
order to assess the global similarity of gene patterns
between PTEN-low and other known gene signatures.
Gene set enrichment analysis was performed by one-
sided Fisher’s exact test (represented as two-sided
Fisher’s z score). To score each human breast tumor
expression profile for similarity to the PTEN-low gene
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signature, a ‘t score’ was derived for the tumor in rela-
tion to the PTEN-low signature patterns, as previously
described [21,22].
Drug interaction test
Enhancement (or attenuation) of growth inhibition with
combination treatment was examined by comparing
combinations to the growth inhibition of each treat-
ment/dose as a single agent within the clinically relevant
range. Briefly, two-agent combinations of kinase inhibi-
tors were explored in 6 x 6 or 4 x 6 dose matrices, under
ED or Tam with or without PTEN-KD. Each experiment
was run in quadruplicate. Cell growth under ED
(+/−PTEN-KD) or Tam (+/−PTEN-KD) alone was set as
the reference (inhibition rate of 0) and used to compute
growth inhibition for single-agent and combination
doses of pairs of kinase inhibitors. For display purposes
as a heatmap, average dose-specific growth inhibition in
each dose/drug matrix was scaled so as to not exceed
100% by dividing by the maximum growth inhibition. In
addition, in each dose matrix we used the Min test of
Laska and Meisner [23], implemented as two one-tailed
t tests to compare each combination to the growth
inhibition at corresponding single-agent doses. The P
value for the Min test is the maximum of the two separ-
ate one-tailed P values. A significant Min test P value
(P ≤0.05) indicates that the combination is superior to
both of the single agents at the same doses, and suggests
enhanced efficacy. Since P values are one-tailed, Min test
P values that are equal to or exceed 0.95 indicate that
the combination is worse (that is has less effect) than at
least one of the single agents, and suggest an attenuation
of effect.
Animal studies
Animal care and animal experiments were in accordance
with and approved by the Baylor College of Medicine In-
stitutional Animal Care and Use Committee (IACUC).
MCF7L-shPTEN xenografts were established in ovariec-
tomized five- to six-week-old athymic mice (Harlan
Laboratories, Indianapolis, IN, USA) supplemented with
E2 pellets by inoculating 6 × 106 cells subcutaneously as
described previously [24]. When tumors reached the vol-
ume of 200 mm3 (two to three weeks), mice bearing the
MCF7L-shPTEN xenografts were randomized to con-
tinuing E2 pellets, or E2 pellets withdrawn (ED) alone or
in combination with Tam or Ful, as previously described
[25]. All arms were fed −/+Dox (200 μg/ml) in the
drinking water [26]. In a separate experiment, mice bear-
ing MCF7L-shPTEN xenografts were randomized to E2,
E2 plus an AKT inhibitor (i) (120 mg/kg, twice daily by
gavage), Ful, or Ful plus AKTi, all arms +Dox. Each arm
contained a minimum of 10 mice. Tumor diameters
were measured once or twice weekly and tumor volume
(vol) was calculated as vol = (width)2 × length/2 [27].
Mice were sacrificed two weeks after treatment or when
tumors reached the volume of 1,000 mm3. Tumor tis-
sues were removed and embedded in paraffin or snap-
frozen in liquid nitrogen for later use.
Statistical analysis
All the statistical analysis was based on the quadruplicated
data. All in vitro experiments were repeated at least three
times. Quantitative data are shown as mean ± standard er-
rors (SE). Significant difference (P <0.05) was determined
by ANOVA or Bonferroni post hoc tests (multiple testing
corrected). We used R software (v2.13.0) for box plot and
GraphPad Prism (v5.04) (GraphPad Software Inc, La Jolla,
CA, USA) for statistical analysis. The Kaplan-Meier sur-
vival and Wilcoxon tests were used for in vivo xenograft
tumor analysis.
Results
Inducible PTEN-KD enhances PI3K signaling, decreases ER
levels and activity, and generates a gene expression
profile associated with the luminal B subtype
To model reduced PTEN in ER+ breast cancer in vitro,
we established stable clones of several ER+ breast cancer
cell lines transduced with a Dox-inducible PTEN short-
hairpin RNA (shRNA) lentiviral system (pINDUCER)
[12]. As depicted in Figure 1A, the pINDUCER inte-
grates both enhanced-GFP (eGFP) and turbo-RFP (tRFP)
to facilitate flow sorting and real-time monitoring of
shRNA expression, respectively. After testing four differ-
ent PTEN-shRNA sequences from pGIPZ clones (Open
Biosystems, Huntsville, Al, USA) (Additional file 1:
Figure S1A and B), we selected two validated shRNA
sequences (#1: V2LHS_231477 and #2: V2LHS_92317)
to construct the pINDUCER-shPTEN lentiviral vector.
The stable MCF7L-shPTEN cell model was established
by lentiviral infection at MOI (multiplicity of infection)
of 0.8, followed by eGFP sorting selection (Additional
file 1: Figure S1C). As expected, the sorted cells with
high-eGFP intensity showed enhanced KD efficiency as
measured by PTEN Western blotting (Additional file 1:
Figure S1D). To model reduced but not absent PTEN,
we used the cell population with low-eGFP intensity for
subsequent experiments. After induction for 48 hours,
the PTEN-KD cells expressing tRFP account for 94.7%
of the total cells measured by flow cytometry. In con-
trast, there is no detectable tRFP in the -Dox cells,
which showed 98.7% eGFP positivity (Figure 1B and C).
Two additional ER+/HER2- cell models (T47D and
BT483) were established by using one (#1) of the two
validated shRNA sequences. Together with MCF7L-
shPTEN, all three models showed the enhanced PI3K/
AKT signaling upon PTEN KD indicated by the in-
creased phosphorylation of AKT (at both Thr 308 and
Fu et al. Breast Cancer Research 2014, 16:430 Page 4 of 17
http://breast-cancer-research.com/content/16/5/430
Figure 1 (See legend on next page.)
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Ser 473) and its substrate GSK3β (Figure 1D). A modest
increase in ERK1/2 phosphorylation in the same models
suggested an impact of reduced PTEN on the mitogen-
activated protein kinase (MAPK) pathway. On the other
hand, ER and its classical downstream gene products
PR and BCL2 were decreased in PTEN-KD cells. The
MCF7L-shPTEN cells with two different PTEN-shRNA
had similar changes in these measured proteins and the
KD efficiency at mRNA level (Additional file 2: Figure
S2A). None of these molecular changes were observed
in the MCF7L-luciferase shRNA (shLuc) cells as the
negative control (Additional file 2: Figure S2B). To
better understand the relationship between PTEN level
and PI3K signaling, we titered the Dox concentration to
knockdown PTEN in a dose-dependent manner. Inter-
estingly, increased phosphorylation of AKT and its sub-
strates (FoxO1/3a and GSK3β) was observed even when
PTEN was only modestly reduced by 50% in both
MCF7L- and T47D-shPTEN cell models (Figure 1E). For
consistency, unless otherwise specified, we used 1 μg/ml
of Dox in the following experiments.
To further explore the impact of PTEN-KD on global
gene expression, total RNA extracted from MCF7L-
shPTEN cells (−/+Dox) was subjected to next-generation
RNA sequencing (RNA-seq). Overall, there were a total of
1,034 genes (368 up, 666 down) differentially expressed
in PTEN-KD cells compared to PTEN-WT cells. As
expected, this PTEN-low gene signature derived from
PTEN-KD is inversely correlated with the signature
derived from cells treated with PI3K inhibitor (CMap
dataset) [28]. Importantly, we also found that this PTEN-
low gene signature is significantly correlated with several
known oncogenic gene signatures from human breast can-
cer with complete PTEN loss [32], AKT transgenic mouse
[29], or epidermal growth factor receptor (EGFR)- or
ERBB2-transfected MCF7 cells (Figure 1F, P <0.05, Pear-
son’s correlations), and is closely correlated with gene sig-
nature from constitutively active MEK-transfected MCF7
cells (P = 0.07) [30]. Further gene enrichment analysis
showed that the genes downregulated by PTEN-KD were
significantly enriched for estrogen (E2)-induced genes
(Cluster B) in vitro [30] (Figure 1G). Indeed, we confirmed
that the mRNA levels of ER, PR, BCL2, and two additional
ER-regulated genes (GREB1 and CAV1) were significantly
decreased in PTEN-KD cells (Additional file 3: Figure
S3A). These data corroborate our previous finding that
activation of PI3K signaling, here through reducing PTEN,
is inversely correlated with ER levels and activity. When
interrogating the gene sets associated with endocrine ther-
apy resistance in our previously published MCF7 xeno-
graft mouse models (Group 1 to 5) [31], we found that the
genes up- or downregulated in the PTEN-KD cells were
significantly enriched for the genes in Group 3 or Group
1/4, which represent the gene sets that are increased or
decreased upon acquired resistance in vivo, respectively
(Figure 1G). These findings suggest that reduced PTEN
levels could contribute to resistance to endocrine therapy
by reducing the level of ER and its signaling activity in
addition to activation of the PI3K pathway, which medi-
ates its own intrinsic growth- and survival-promoting
signals.
Next we asked to what extent the shPTEN cell model
recapitulates the influence of reduced PTEN in luminal
ER+ breast cancer. We used our PTEN-low gene signa-
ture to interrogate the microarray datasets from TCGA
[11] and the mega-set Compendium [18]. As shown in
Figure 1H, the luminal B subtype of breast cancer has a
significantly higher score than luminal A in both data-
sets. This difference in PTEN-low gene signature score
between two luminal subtypes can be reflected at least
partially by the significantly lower PTEN mRNA levels
in luminal B than in luminal A subtype in both datasets
(Additional file 3: Figure S3B). Since all of the cell
models we used have endogenous PIK3CA mutations
(E545K in MCF7L, H1047R in T47D, and E542K in
BT483), we asked whether ER+ tumors with different
PTEN levels have a distinct distribution of PIK3CA muta-
tions. Within 349 ER+ tumors with matched information
(See figure on previous page.)
Figure 1 PTEN-KD enhances PI3K signaling, reduces expression of ER and its regulated genes, and promotes expression profile of
genes associated with luminal B subtype. (A) Diagram of the lentiviral pINDUCER vector. (B) Fluorescence microscopy (20×) shows the eGFP
and tRFP expression in MCF7L-shPTEN cells after Dox induction for 48 h. (C) The quantification of the positive population of eGFP and tRFP cells
was analyzed by flow cytometry. (D) After three days of Dox induction, the cell lysates of shPTEN cell models were subjected to Western blotting.
Numbers under each blot indicate protein densitometry normalized to β-actin (values in -Dox cells were set as 1). (E) Cell lysates from MCF7L-
shPTEN and T47D-shPTEN cells after five days induction with a range of Dox doses were blotted by the indicated antibodies (densitometry shown
under the PTEN blotting). (F) PTEN-low gene signature derived from PTEN-KD cells representing the differentially expressed genes compared to
-WT cells was correlated with known gene signatures related to growth factor signaling [28-30]. Heat map of t statistic indicates the global
similarity between signatures based on the Pearson’s correlations. (G) Up- or downregulated (DN) genes in PTEN-KD cells were analyzed for gene
enrichment (one-sided Fisher’s exact test) in the gene sets of endocrine resistant xenograft tumors (Group 1 to 5) [31] or E2-induced MCF7 cells
(Cluster B) [30]. (H) Box plot shows the PTEN-low gene signature scores of each ER+ luminal tumor from datasets of TCGA [11] and Compendium
[18]. The mean value ± standard deviation of all samples in each subtype is marked within the box plot in red (****P <0.0001, Student’s t test). Dox,
doxycycline; E2, β-estradiol; ED, estrogen deprivation; eGFP, enhanced GFP; ER, estrogen receptor α; KD, knockdown; PI3K, phosphatidylinositol
3-kinase; PTEN, phosphatase and tensin homolog; TCGA, The Cancer Genome Atlas; tRFP, turbo-RFP.
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for both events (data from TCGA), we found that there is
no significant association between PIK3CA mutations and
PTEN mRNA levels (Additional file 4: Figure S4).
Moderate PTEN reduction decreases sensitivity to
endocrine therapies in ER+/HER2- breast cancer cells
To assess the effect of reduced PTEN on endocrine sen-
sitivity, cells were treated with E2 control, ED, tamoxifen
(Tam), or fulvestrant (Ful), and cell number was moni-
tored using an in situ cell cytometer (Celigo, Nexcelom
Bioscience). As shown in Figure 2A-D, while cell growth
was strongly inhibited by anti-estrogen treatment in
PTEN-WT cells, growth inhibition was substantially less
in PTEN-KD cells. PTEN-KD significantly attenuated
the anti-estrogen effect in blocking cell cycle S-phase
entry, which partially explains the cell growth advantage
over PTEN-WT cells (Additional file 5: Figure S5A). The
decreased endocrine sensitivity induced by PTEN-KD
was not observed in MCF7L-shLuc cells (Additional
file 2: Figure S2C). Reduced endocrine sensitivity was
further confirmed by colony formation assay in MCF7L-
shPTEN cells, and by tumorsphere formation assay in the
BT483-shPTEN model (Additional file 5: Figure S5B
and C). Importantly, in both MCF7L- and T47D-shPTEN
cells with dose-dependent PTEN decreasing levels as
shown in Figure 1E, even modest reduction in PTEN
caused attenuated growth inhibition by endocrine regi-
mens (Figure 2E and F). Specifically, PTEN-KD by the
lowest dose of Dox, in some instances, showed no differ-
ence in reducing endocrine sensitivity compared to the
highest extent of PTEN-KD (Figure 2E, Tam treatment
group).
Figure 2 Moderate reduction in PTEN decreases endocrine sensitivity in ER+/HER2- breast cancer cell models. MCF7L-shPTEN cells with
two different shRNA sequences (#1 and #2) (A and B), T47D-shPTEN (#1) cells (C), and BT483-shPTEN (#1) cells (D) were grown in PRF medium with 5%
CS-FBS under −/+Dox for three days, then treated with E2 (1 nM) as control, continuing the same medium (ED), Tam (100 nM), or Ful (100 nM)
for five days in 96-well plates. Cell growth (%) at day 5 in all anti-estrogen groups (ED, Tam, and Ful) was normalized to E2 −/+Dox control. There is
no noticeable change in cell growth between E2-Dox and E2 + Dox groups. Cell growth was monitored daily by in situ cell cytometry (Celigo).
(E and F) MCF7L-shPTEN and T47D-shPTEN cells were prepared as before with an additional range of Dox induction and subjected to endocrine
treatment. Cell growth (%) at day 5 in all anti-estrogen groups (ED, Tam, and Ful) was normalized to E2 −/+Dox control. The Bonferroni post hoc
test was used for all pairwise comparisons (*P <0.05, **P <0.01, ***P <0.001). CS-FBS, charcoal stripped-fetal bovine serum; Dox, doxycycline; E2,
β-estradiol; ED, estrogen deprivation; ER, estrogen receptor α; Ful, fulvestrant; HER2, human epidermal growth factor receptor 2; PRF, phenol-red
free; PTEN, phosphatase and tensin homolog; shRNA, short hairpin RNA; Tam, tamoxifen.
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PTEN-KD leads to endocrine resistance in xenograft
tumors
To determine the effect of PTEN-KD on endocrine sen-
sitivity in an in vivo xenograft model, ovariectomized
nude mice bearing MCF7L-shPTEN xenografts were
randomized to E2, E2 withdrawal (ED), or ED combined
with Tam or Ful, all with -/+Dox to modulate PTEN
levels. The dual-fluorescence in the pINDUCER system
allows the real-time assessment of shRNA expression as
well as tumor growth by live animal imaging [12]. As
shown in Figure 3A, at week 6 after randomization,
there is no detectable shPTEN expression in all -Dox
xenograft tumors shown by the negative tRFP signal.
The positive eGFP signal confirms the persistent genome
Figure 3 PTEN-KD confers endocrine resistance in the xenograft mouse model. (A) Fluorescent live images showed MCF7L-shPTEN
xenograft tumors at week 6 after randomization. Fluorescent red suggests the expression of tRFP with the color bar indicated at bottom. The
tumors without a red signal (arrow indicated) show the fluorescent green (eGFP expression) in the insets. (B-E) Growth curves of xenograft
tumors under E2, ED, Tam, or Ful, all −/+Dox (n ≥10 in each arm). The IHC staining of PTEN (F), pAKT-S473 (H), and Ki67 (J) in tissue microarrays
of xenograft tumors after two weeks of treatment was quantified as the Allred scores of cytoplasmic PTEN (G) and cytoplasmic pAKT-S473 (I), or
as the proportion of Ki67 positive cells (K). n = 6 for each arm; scale bar, 50 μm (F and H), 100 μm (J). The Bonferroni post hoc test was applied for
paired comparisons between −/+Dox in each endocrine group, or between the anti-estrogen and E2 groups (*P <0.05, **P <0.01, ***P <0.001).
Dox, doxycycline; E2, β-estradiol; ED, estrogen deprivation; eGFP, enhanced GFP; Ful, fulvestrant; IHC, immunohistochemical; KD, knockdown;
PTEN, phosphatase and tensin homolog; Tam, tamoxifen; tRFP, turbo-RFP.
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integration of the pINDUCER cassette. In contrast,
all +Dox tumors expressed tRFP, which quantitatively
matched the tumor size measurements. The positive tRFP
signal was maintained in all palpable +Dox tumors
throughout the life span of the mice, assuring the persist-
ence of shPTEN expression in this xenograft mouse model.
As expected, all the xenografts in the E2 arm (−/+Dox)
reached the 1,000 mm3 harvest size in less than 50 days
(Figure 3B). In -Dox groups, all of the anti-estrogen arms
led to significant tumor regression, and the median time
to tumor regression (TTR), defined as a 50% reduction in
tumor size since randomization, was 25, 24, and 17 days,
respectively (Figure 3C-E; Table 1). In contrast, PTEN-KD
significantly delayed tumor regression in the ED and Ful
arms (Table 1, median TTR of 108 and 107 days, respect-
ively), and caused tumors to grow without regression in
the Tam arm. Also in the Tam arm, the median time to
tumor progression (TTP), defined as the tumor size doub-
ling since randomization, was significantly shortened in
PTEN-KD compared to -WT tumors (Figure 3D; Table 1,
54 days vs. 86 days). Although at 470 days of follow-up
the median TTP had not yet been achieved in ED and Ful
arms, the increased progression rate was obvious in
PTEN-KD versus -WT tumors (Figure 3C and E; Table 1,
43% vs. 13%, and 47% vs. 14%, respectively).
To better understand endocrine resistance caused by
reduced PTEN in vivo, IHC assay was performed in a
tissue microarray including tumor samples collected
after two weeks of treatment. An optimized PTEN IHC
protocol was developed in a PTEN index-slide test
(Additional file 6: Figure S6). As expected, PTEN was
significantly decreased in tumors from all +Dox groups
(Figure 3F and G). Of note, the positive staining was also
evident in some mouse stromal cells. Interestingly, a
slight increase in PTEN was observed with endocrine
treatment, especially in the Tam arm of PTEN-KD tu-
mors compared to E2 control. Phosphorylation of AKT
(pAKT) at S473 was increased in PTEN-KD compared
to -WT tumors, especially in the E2 and Ful arms
(Figure 3H and I). An acute increase in pAKT in the first
two weeks of endocrine therapy was seen in PTEN-WT
tumors, but was not significant in PTEN-KD tumors,
probably due to the increased level already existing in
the E2 control. A modest decrease in the proliferation
marker Ki67 was found in PTEN-WT tumors receiving
Tam, and a significant reduction was observed in ED
and Ful arms (Figure 3J and K). PTEN-KD caused an in-
crease in Ki67 in all anti-estrogen treatment arms, and
reached statistical significance in the Ful arm. These data
further support the conclusion that PTEN-KD contrib-
utes to lower endocrine sensitivity and eventual progres-
sion in ER+ breast cancer.
Kinase inhibitors downstream of PI3K enhance endocrine
therapy by overcoming resistance due to reduced PTEN
The PI3K and MAPK pathways downstream of growth
factor receptors (GFRs) coordinate and crosstalk to drive
cancer cell proliferation and survival. Several feedback
loops have been described in which inhibition of one
pathway leads to activation of the other [33,34]. Even in
the same PI3K pathway, the AKT/mTOR axis is also
regulated by a feedback loop, suggesting the need for
combination therapy [35]. It has been shown that
pan-PI3K inhibitors exhibited preferential inhibition of
tumor cells bearing PIK3CA mutations, while their activ-
ity in PTEN deregulated models of breast cancer is con-
troversial [6,36]. In this study, we focused on inhibitors
of several key nodes in the PI3K and MAPK pathways
including AKT, mTOR, or MEK, alone or in combin-
ation, to block compensatory pathways activated with
single-agent therapy. AZD2014 and AZD5363 are ATP-
competitive inhibitors that block mTORC1/2 and AKT
signaling with Ki values of 2 nM (mTOR) and <10 nM
(AKT) [37,38]. Selumetinib (AZD6244, ARRY-142886) is
Table 1 Tumor regression and progression under endocrine therapy in the MCF7L-shPTEN xenograft model with
PTEN-WT (−Dox) or -KD (+Dox)
Treatment TRa (%) TTRb (95% CI) Pe TP470c (%) TTPd (95% CI) P
E2-Dox 0 NAf (NA-NA) 1 100 8 (5–12) 0.671
E2 + Dox 0 NA (NA-NA) 100 10 (6–13)
ED-Dox 100 25 (6–39) 0.011 13 NA (223-NA) 0.098
ED + Dox 64 108 (30-NA) 43 NA (41-NA)
Tam-Dox 71 24 (9-NA) 0.002 71 86 (73-NA) 0.022
Tam + Dox 24 NA (43-NA) 94 54 (36–71)
Ful-Dox 100 17 (6–24) <0.001 14 NA (462-NA) 0.107
Ful + Dox 73 107 (38–198) 47 NA (101-NA)
aTR is the fraction of mice achieving tumor regression, defined by the tumor size halving since the randomization; bTTR is the median time to tumor regression
with 95% confidence interval; cTP470 is the fraction of mice experiencing tumor progression within 470 days after treatment, defined by the tumor size doubling
since the randomization; dTTP is the median time to tumor progression with 95% confidence interval; eP value is based on the generalized Wilcoxon test
comparing the −/+Dox groups in each endocrine treatment arm; fNA = not-achieved. PTEN, phosphatase and tensin homolog; WT, wild-type; Dox, doxycycline; KD,
knockdown; TTR, time to tumor regression; TTP, time to tumor progression; E2, β-estradiol; ED, estrogen deprivation; Tam, tamoxifen; Ful, fulvestrant.
Fu et al. Breast Cancer Research 2014, 16:430 Page 9 of 17
http://breast-cancer-research.com/content/16/5/430
a non-ATP-competitive inhibitor of MEK with an IC50
for inhibition of MEK in vitro and in cells of approxi-
mately 12 nM [39]. The concentration chosen for
the single-kinase inhibitors (i) targeting mTORC1/2
(mTORi), AKT (AKTi), or MEK (MEKi) was based on
clinically relevant concentrations in patients (AstraZeneca
data on file), and was validated by the decreasing
phosphorylation of the kinase substrates in MCF7L cells
(Additional file 7: Figure S7). Adding a single inhibitor
produced significantly more growth inhibition than E2,
ED, or Tam alone (Figure 4A-C). PTEN-KD attenuated
the growth inhibitory effect of single inhibitors in the pres-
ence of endocrine therapy, especially for the mTORi in
the ED group (by IC50 assay, data not shown). ED was less
effective than Tam, alone or in combination with the in-
hibitors in this cell model, perhaps because signaling from
the PI3K pathway can cause ligand-independent activation
of the ER [40,41].
Next we investigated combinations of two kinase in-
hibitors together with endocrine treatment, to block
compensatory pathways. In general, combinations of
the inhibitors at the specific doses were more effective
in both PTEN-WT and -KD cells. The mTORi plus
AKTi was highly effective in the presence of E2, ED, or
Tam in PTEN-WT and -KD cells, especially the latter
(Figure 4A-C). The AKTi plus MEKi was most effective
with Tam and was cytotoxic even in PTEN-KD cells
(Figure 4C).
To better understand drug interactions within the
range of clinically relevant doses, we extended the above
testing by following a 6 × 6 or 4 × 6 drug combination
matrix under ED (+/−PTEN KD) or Tam (+/−PTEN
KD). Figure 4D-I display the calculated average dose-
specific growth inhibition in each dose/drug matrix.
Using the Min test, the significance and direction of the
drug interaction (that is, enhancement (P ≤0.05) or at-
tenuation (P ≥0.95) of growth inhibition) was established
for all different drug/dose combinations (Additional
file 8: Figure S8) and summarized as the percentage of
significant interactions within each matrix (Figure 4J-K).
This analysis revealed that enhancement of inhibitory
effect from any two-drug combination compared to
either inhibitor alone was present within all tested drug
combination matrixes (P ≤0.05, Min test). Within the
matrix, PTEN-KD led to a decreased percentage of com-
binations of mTORi plus AKTi with enhanced inhibitory
effect under either ED (Figure 4J) or Tam (Figure 4K),
whereas the percentage of combinations with attenuated
effect compared to single inhibitors (P ≥0.95, Min test)
was increased (from 0% to 8% in ED, and from 8% to
16% in Tam). Similarly, due to PTEN-KD, the number of
combinations with enhanced effect was substantially
lower in mTORi plus MEKi under ED (Figure 4J, from
67% to 20%). In contrast, a slightly increased number of
combinations with enhanced effect was seen in PTEN-
KD cells treated with AKTi plus MEKi under Tam
(Figure 4K, from 60% to 73%). These data suggest that
there is drug interaction heterogeneity within the experi-
mental settings with different types of inhibitors, PTEN
status, and endocrine therapy.
AKTi combined with fulvestrant inhibits PI3K downstream
signaling, induces apoptosis, and accelerates regression
of PTEN-KD xenograft tumors
Since the potent anti-estrogen Ful inhibits both ligand-
dependent and -independent ER signaling, we next in-
vestigated its inhibitory effects in the absence of E2 by
combining it with the various kinase inhibitors. In
MCF7L cells, Ful inhibited cell growth more potently
than ED or Tam in both PTEN-WT and -KD cells, al-
though PTEN-KD decreased its activity (Figure 5A and
B). Most combinations with a kinase inhibitor reduced
cell number below baseline indicating a cytotoxic and
not just a cytostatic effect. In the presence of Ful, at the
concentrations tested the AKTi was the most potent
single-kinase inhibitor in both PTEN-WT and -KD cells,
and the only inhibitor that induced cytotoxic effects in
the PTEN-KD cells. Of note, in PTEN-KD cells, the
MEKi combined with Ful failed to induce cytotoxicity
(Figure 5B). However, the addition of the MEKi to the
AKTi significantly enhanced the cytotoxic effect com-
pared to single drug alone in PTEN-WT cells, with a
similar trend in the PTEN-KD cells. The combination of
the AKTi or mTORi with Ful induced more apoptosis
than Ful alone in PTEN-KD cells (Figure 5C).
Focusing on the MCF7L-shPTEN model, we examined
the effects of the AKTi, mTORi, or MEKi, -/+Ful treat-
ment on various signaling intermediates by Western
blotting. As expected, addition of a single-kinase inhibi-
tor effectively suppressed the phosphorylation of corre-
sponding substrates of mTOR (S6, 4EBP1), AKT
(GSK3β), and MEK (ERK1/2) after 48 hours of exposure
(Figure 5D, −/+Dox, lane 3, 5, 7, compared to lane 1).
Also as expected, the AKTi increased phosphorylation of
AKT at T308 and S473 [37]. In PTEN-KD cells, the in-
creased phosphorylation of AKT at T308 with the
mTORi is probably due to the relief of a negative feed-
back loop from mTOR to inhibit IRS1-mediated PI3K
signaling, which was further strengthened in cells with
low PTEN (Figure 5D, lane 3 compared to lane 1)
[42,43]. Both the AKTi and the mTORi decreased phos-
phorylation of mTOR substrates (S6, 4EBP1), but only
the AKTi kept suppressing the AKT signaling in both
PTEN-WT and -KD cells, as shown by the reduced
phosphorylation of GSK3β (Figure 5D, lane 3 and 5
compared to lane 1). Ful successfully suppressed ER ac-
tivity, shown by the decreased levels of ER-regulated
genes (IGF1R, CyclinD1, and BCL2). The combination
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of the mTORi or the AKTi with Ful further increased
the levels of cleaved PARP (c-PARP), another apoptotic
marker, compared to either agent alone in both PTEN-
WT and -KD cells, especially in the latter (Figure 5D,
comparison of lane 3 vs. lane 1 and 2; lane 5 vs. lane 1
and 4).
Since the AKTi, among the three inhibitors with the
concentrations tested, shows the most potent efficacy as
a single-kinase inhibitor when combined with Ful, we
verified this combination in all three shPTEN ER + cell
models. Indeed, this combination was significantly more
effective than either drug alone (Figure 5E-G), though in
BT483 cells, no cytotoxic effect was observed. These
findings strongly suggest that an AKTi combined with
Ful may be an effective therapy for ER+/HER2- breast
cancer, especially when the PI3K pathway is activated by
low PTEN. We further tested this hypothesis in a mouse
xenograft model by focusing on the tumor response
defined by tumor regression to half of the size of the tu-
mors at randomization. We used the AKTi at 120 mg/
kg, twice daily by gavage, a dose that did not cause
obvious toxicity or weight loss (data not shown).
Kaplan-Meier survival analysis was performed to com-
pare tumor response in the three arms (AKTi alone, Ful
alone, and the combination). A generalized Wilcoxon
test showed significant differences in time to tumor
halving among the three arms (Figure 5H). No tumors
regressed when the AKTi was added to estrogen-treated
mice. The AKTi combined with Ful, however, signifi-
cantly accelerated tumor regression compared to Ful
alone, with median time to tumor halving of 12 days and
35 days, respectively.
Discussion
In this study, we provide evidence that in our model
system, even partial reduction in PTEN, without
complete loss, is sufficient to activate PI3K signaling,
confer endocrine resistance, and trigger a gene signa-
ture that is associated with the luminal B subtype of
breast cancer. In addition, we evaluated the efficacy of
various combination therapies co-targeting ER and ki-
nases downstream of PI3K signaling to treat PTEN-low
ER+/HER2- breast cancer. We found that the efficacy of
the different combinatorial therapies varied by the
endocrine regimens and the PTEN levels. Importantly,
our inducible PTEN-shRNA model system allowed us
to evaluate the effects of partial PTEN reduction on
endocrine resistance and to explore new strategies to
overcome this resistance in the in vivo setting. Indeed,
both our in vitro and in vivo experiments showed that
AKT inhibition combined with fulvestrant is a particu-
larly effective approach to overcome endocrine resist-
ance due to reduced PTEN levels.
The PTEN level appears to be tightly controlled both
transcriptionally and post-transcriptionally [44], with
evidence showing promoter methylation in PTEN sup-
pression in a Tam-resistant cell model [45]. Some onco-
genic microRNAs have been found to target PTEN
mRNA, and a recent study suggested that this regulation
has prognostic potential in patients with luminal breast
cancers [46]. PTEN loss (by IHC) and PIK3CA muta-
tions are reported not to be mutually exclusive in breast
cancers [6], suggesting that they have different contribu-
tions to tumor pathophysiology and pathway activation.
We found that PTEN mRNA levels do not correlate with
PIK3CA mutations in ER+ breast cancer, suggesting that
the contribution of decreased PTEN to activation of
PI3K signaling is independent of PIK3CA mutations.
Similarly, there is no significant difference in the fre-
quency of tumors with PIK3CA mutations among those
tumors with the highest and lowest quartiles of PTEN
protein expression measured by RPPA [11]. In fact, we
found that activation of the PI3K pathway in our three
ER+/HER2- cell models with mutant PIK3CA, was sub-
stantially enhanced upon PTEN-KD. Therefore, in
light of the fact that PIK3CA mutations are associated
with a phenotype of relatively low mTOR signaling and
better outcome in ER+/HER2- breast cancer [5,6], it
may be that decreased PTEN level, and perhaps the
levels of other phosphatases regulating this pathway
(See figure on previous page.)
Figure 4 Efficacy of combination therapy varies by PTEN levels, type of endocrine therapy, and combined kinase inhibitors. MCF7-
shPTEN cells were pre-treated in PRF medium with 5% CS-FBS and −/+Dox for three days. Bar charts presented the % of cell growth of MCF7L-
shPTEN cells treated for five days with single or two-agent combination kinase inhibitors (mTORi, 0.2 μM; AKTi, 1 μM; MEKi, 1 μM), under E2 (A),
ED (B), or Tam (C) condition, all −/+Dox (gray/red color). Cell growth in five days of the E2 (−/+Dox) groups was used as the normalization
control. The Bonferroni post hoc test was performed for paired comparisons between single-kinase inhibitors and DMSO (drug carrier control)
(#P <0.05), or between a two-agent kinase inhibitor combination and either agent alone (*P <0.05, **P <0.01, ***P <0.001). Heat maps were used
for all calculated % of growth inhibition (scaled so as to not exceed 100% by dividing by the maximum growth inhibition within each matrix) in
two-agent combinations of kinase inhibitors: mTORi plus AKTi (D and G), mTORi plus MEKi (E and H), or AKTi plus MEKi (F and I), all under ED or
Tam. Cell growth under ED or Tam without kinase inhibitor was set as 100% (0% of growth inhibition) for the normalization control. Percentages
of combinations among each matrix with enhanced (P ≤0.05) or attenuated (P ≥0.95) effect compared to single drug alone (tested by the
Min test) were summarized in (J) (under ED) and (K) (under Tam). AKT, protein kinase B; CS-FBS, charcoal-stripped-FBS; Dox, doxycycline; E2,
β-estradiol; ED, estrogen deprivation; Ful, fulvestrant; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian target of rapamycin; PRF,
phenol-red free; PTEN, phosphatase and tensin homolog; Tam, tamoxifen.
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such as INPP4B [47], represents an important mechan-
ism resulting in the more aggressive phenotype seen in
luminal B breast cancer [48].
Our data are consistent with reports that a PTEN-loss
gene signature, derived from a comparison of PTEN+/−
tumors by IHC, is also associated with the luminal B sub-
type [5] and with a poor recurrence-free survival after
Tam in ER+ breast cancer patients [32]. Importantly, we
showed that PTEN reduction, without complete loss, de-
creased the rate of tumor regression with both ED and
Ful, and increased the rate of late progression. PTEN-KD
led to early tumor progression with Tam treatment, sug-
gesting that Tam may have acquired more estrogen agon-
ist and less antagonist activity, similar to the effect we
showed previously in a HER2-overexpressing xenograft
model [49]. These data indicate the need for a clinically
Figure 5 Fulvestrant combined with the AKT inhibitor potently suppresses GFRs downstream signaling, induces apoptosis, and
accelerates tumor regression. (A and B) MCF7L-shPTEN cells were prepared as before and treated with Ful combined with single or two-agent
kinase inhibitors, under −/+Dox (gray/red color) conditions. Cell growth was analyzed the same way as in Figure 4. (C) Cells were treated with
Ful combined with single-kinase inhibitors (−/+Dox) for 48 hours and stained with Annexin-V-APC. Flow cytometer analysis was performed to
quantify the apoptotic cells with positive staining. (D) MCF7L-shPTEN cells were prepared as before and then treated with Ful alone, or E2 or Ful
in combination with mTORi (0.2 μM), AKTi (1 μM), or MEKi (1 μM). Cell lysates were harvested after 48 hours of treatment and immunoblotted
with the indicated antibodies. Cells of MCF7L (E), T47D (F), and BT483 (G) -shPTEN models were prepared as before (all + Dox) and then treated
with E2, Ful, or each in combination with AKTi (1 μM). Cell growth within five days was normalized to the E2 groups. (H) Kaplan-Meier plots of
proportion of tumor burden without response (defined ‘response’ as tumor size halving since randomization) within 60 days of treatment of AKTi
alone in the presence of supplemented E2 pellets, or Ful combined with drug carrier (Veh) or AKTi without E2 pellets (n ≥10 in each arm). The
AKTi (120 mg/kg) or drug carrier (Veh) was administered twice daily by gavage for both E2 and Ful arms. The Wilcoxon method with adjusted pairwise
comparison was applied. All the pairwise comparisons of cell growth were performed by the Bonferroni post hoc test (*P <0.05, **P <0.01, ***P <0.001).
AKT, protein kinase B; Dox, doxycycline; E2, β-estradiol; Ful, fulvestrant; GFRs, growth factor receptors; MEK, mitogen-activated protein kinase kinase;
mTOR, mammalian target of rapamycin; PTEN, phosphatase and tensin homolog.
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useful quantitative assay with optimized cutoffs for PTEN
itself, or the establishment of other biomarkers to indicate
that the PI3K pathway has been activated [50]. The failure
of assays of complete PTEN loss to correlate with clinical
endpoints such as therapy resistance, especially the resist-
ance to HER2-targeted therapies [51], may be due to the
fact that only modest reductions in PTEN are required to
activate downstream signaling.
Our study provides a possible strategy for selecting a
signal transduction inhibitor to test with an endocrine
therapy in ER+ breast cancer. Numerous inhibitors of
various pathways that have been implicated in endocrine
resistance are in development, and it would be challen-
ging to test all of the various combinations with different
endocrine therapies in clinical trials. Here we extensively
studied combinations of three inhibitors targeting the
downstream signaling of the PI3K pathway with the
three major types of endocrine therapy in our PTEN-KD
cell models. The mTORi alone or combined with the
AKTi, at the clinically relevant doses selected, was a
most effective agent on a background of E2 or ED. The
AKTi alone or combined with the MEKi was most ef-
fective when combined with Ful. The effectiveness of the
combination of the mTORi everolimus with the aroma-
tase inhibitor exemestane in the BOLERO-2 trial sug-
gests that the preclinical model may have predicted
correctly [52]. It will be interesting to further investigate
in this study whether partial reduction in PTEN levels is
related to treatment outcome. Our data also suggest that
these inhibitors deserve clinical trial in patients with lu-
minal A tumors without PI3K pathway activation, since
they were effective in cells without PTEN-KD. Perhaps
they were effective by blocking the PI3K pathway that
can become activated by increased signaling from GFRs
once ER is blocked [41].
PTEN downregulation decreases not only sensitivity to
endocrine therapy, but also sensitivity to the kinase in-
hibitors, perhaps due to the multiple feedback loops ac-
tive in this complex network that may require multiple
inhibitors in combination to overcome [53,54]. The en-
hanced efficacy of mTORi plus AKTi was seen under
both ED and Tam, though the efficacy was attenuated at
some doses by the PTEN-KD. The limited efficacy in pa-
tients treated with the mTOR inhibitor rapamycin alone
may be explained by inactivating a negative feedback
loop resulting in reactivation of AKT [35,43]. A combin-
ation of mTORi plus AKTi might improve the efficacy
of the mTORi alone. PTEN-KD cells were also sensitive
to the combination of AKTi plus MEKi with either Tam
or Ful. A synergistic effect with these inhibitors was also
previously reported in a basal-like breast cancer xeno-
graft model with either intact or deleted PTEN [55].
Therefore, optimal treatment for ER+ breast cancer with
PI3K pathway activation may depend not only on the
specific type of endocrine therapy, but also on the par-
ticular signaling inhibitor used to block the pathway.
Our study suggests that the most potent combination
to test in patients with evidence of PI3K pathway activa-
tion may be an AKT inhibitor, together with Ful. Ful is
an anti-estrogen with little or no E2-agonist activity.
Furthermore, Ful is an ER degrader and would thus be
more effective than ED or Tam when ER is activated in a
ligand-independent manner [40]. ER and its coregulators
are phosphorylated and activated by PI3K signaling, here
through PTEN KD, which may convert ER from a clas-
sical ERE-mediated transcription factor to a non-
classical transcription factor mediated by its binding to
other sites on DNA [40,41]. This suggests that in ER+
breast cancer with high PI3K signaling, downregulation
of ER may be the preferred endocrine therapy. Other
studies using the long-term estrogen-deprivation
(LTED)-resistant models with increased PI3K signaling
further support this conclusion [56,57]. A recent report
that Ful can induce HER ligands in ER+ breast cancer
cells and thereby activate the PI3K/AKT pathway may
explain the efficacy of the combination of Ful with the
AKTi [58]. Our observation that the levels of AKT phos-
phorylation are increased in MCF7L xenograft tumors
after two weeks of Ful treatment provides an additional
rationale for combining AKT inhibition with Ful, a com-
bination that should be tested in the clinic.
Conclusions
This study shows that moderate PTEN reduction en-
hances multiple PI3K downstream signals, resulting in a
global change of gene expression profile toward the lu-
minal B subtype and endocrine resistance. Overcoming
endocrine resistance by adding single or combined kin-
ase inhibitors targeting mTOR, AKT, or MEK is a prom-
ising strategy but needs optimization based on PTEN
levels and the type of endocrine agents used. Thus, the
PTEN level may serve as a predictive marker for endo-
crine therapy and may also guide the design of combina-
torial therapy. Among the single-agent kinase inhibitors,
an AKT inhibitor best potentiates the efficacy of fulves-
trant both in vitro and in vivo, providing a rationale for
evaluating this combination in patients with ER+ tumors
with reduced PTEN.
Additional files
Additional file 1: Figure S1. PTEN shRNA sequences were verified in
breast cancer cells sorted by different eGFP intensity. (A) BT483 cells
were infected with pGIPZ-shPTEN lentivirus and sorted by low (L)/high
(H) intensity of eGFP. (B) Western blotting of PTEN in BT483 cells with
four different shRNA sequences from pGIPZ vector (V2LHS series). The
shRNA of luciferase (shLuc) was used as the negative control. (C) MCF7L
cells were infected with pINDUCER-shPTEN lentivirus and sorted the same
way as in A. (D) MCF7L-shPTEN_#1 cells with one of the verified shPTEN
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sequences were sorted for L/H- eGFP intensity and induced by Dox for
two or five days. MCF7L-shLuc cells were used as knockdown (KD) control.
Cell lysates were subjected to Western blotting of PTEN and β-actin.
Additional file 2: Figure S2. The effect of consistent KD by two PTEN
shRNAs on MCF7L cells was not seen in the non-specific shRNA control.
(A) PTEN mRNA levels were measured by qRT-PCR in MCF7L-shPTEN cells
with two different shRNA sequences (#1 and #2). (B), MCF7L-shLuc cell
lysates under −/+Dox were subjected to Western blotting as indicated. (C),
MCF7L-shLuc cells were cultured in phenol-red free (PRF) medium with 5%
charcoal-stripped (CS)-FBS and −/+Dox for three days before being subjected
to E2 (1 nM), ED, Tam (100 nM), or Ful (100 nM). Cell growth (%) was
normalized to E2 controls (−/+Dox). Bonferroni post hoc comparison was
performed within each treatment (−/+Dox) (N.S., not significant).
Additional file 3: Figure S3. Reduced PTEN causes decreased ER and
its regulated genes, and is associated with the luminal B subtype of
breast cancer. (A) The mRNA levels of ER and its regulated genes were
measured by qRT-PCR in MCF7L-shPTEN cells in −/+Dox for three days.
GAPDH mRNA levels were used as internal control. Gene expression in
cells with the ED condition was used as a normalization control (set as 1).
(B) Box plot shows the PTEN mRNA levels in the luminal A and B tumors
from datasets of TCGA and Compendium. The mean value ± standard
deviation of all samples in each subtype is marked on the box plot in
red. All the pairwise comparisons were performed by Bonferroni post hoc
test (*P <0.05, **P <0.01, ***P <0.001).
Additional file 4: Figure S4. PTEN mRNA levels are not correlated with
PIK3CA mutations in ER+ breast cancer. A total of 349 ER+ luminal tumors
from the TCGA dataset were ranked from high to low PTEN mRNA levels
(log2 transformed and median-centered). The status of PIK3CA gene
mutations (red line indicates mutated) was aligned to the corresponding
tumors. Spearman’s test of the correlation of PTEN mRNA levels and
PIK3CA mutations was applied (N.S., not significant).
Additional file 5: Figure S5. PTEN KD decreases endocrine sensitivity
in shPTEN cell models. (A) PTEN KD attenuated the blocking of S-phase
entry by anti-estrogen treatment in MCF7L-shPTEN cells. Cell cycle distribution
was measured in MCF7L-shPTEN cells under −/+Dox and endocrine treatment
for three days. Cell population in G1 phase was compared between −/+Dox
in each treatment group. (B) Colonies of MCF7L-shPTEN cells under −/+Dox
and endocrine treatment for three weeks were stained by crystal violet.
Quantification of colony formation was performed by ImageJ software. (C)
Tumorspheres of BT483-shPTEN cells under −/+Dox and endocrine treatment
for two weeks were scanned and quantified by cell cytometry (Celigo).
Inset image shows the tRFP signal under fluorescence scanning. Scale
bar, 100 μm. The Bonferroni post hoc test was used for all pairwise
comparisons between −/+Dox (*P <0.05, **P <0.01), or between E2
and anti-estrogen groups (#P <0.05).
Additional file 6: Figure S6. The optimized PTEN IHC protocol was
verified in a cell pellet index array. (A) MCF7L-shPTEN cells were cultured
in medium containing Dox (1 μg/ml) for different days, or a dose range
of Dox for seven days, before being fixed in 10% neutral-buffered formalin
and then embedded in paraffin. The processed cell pellets were organized
in one slide (index array) as shown. (B) Representative IHC images for PTEN
staining in the index array. Scale bar, 200 μm.
Additional file 7: Figure S7. Kinase inhibitors at the single dose used
in cell growth assays effectively suppress the corresponding downstream
signaling. MCF7L-shPTEN cells were grown in PRF medium with 5%
CS-FBS for three days and then treated with DMSO (control), mTORi
(0.2 μM), AKTi (1 μM), or MEKi (1 μM) for 3 hours or 24 hours. The cell
lysates were harvested for the measurement of the phosphoproteins by
Western blotting.
Additional file 8: Figure S8. Statistical analysis for drug interactions
was performed by the Min test as described in Methods and the results
are presented by heat maps showing the color-scaled P values for each
drug combination matrix under ED (A-C) or Tam (D-F).
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